Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Orelabrutinib in Central Nervous System Diseases: NCT06901999 Clinical Landscape Report 2026
15 October 2026
NCT06901999 clinical landscape for Central Nervous System Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide Phosphate in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: NCT06905509 Clinical Landscape Report 2026
15 October 2026
NCT06905509 clinical landscape for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: endpoints, sponsor, phase, geography, readouts, a…
9 min read
Bulumtatug fuvedotin in Triple Negative Breast Cancer: NCT06908928 Clinical Landscape Report 2026
15 October 2026
NCT06908928 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axicabtagene Ciloleucel in Primary mediastinal large B-cell lymphoma recurrent: NCT06912529 Clinical Landscape Report 2026
15 October 2026
NCT06912529 clinical landscape for Primary mediastinal large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and dev…
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT06910072 Clinical Landscape Report 2026
15 October 2026
NCT06910072 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IDOV-Immune in Sarcoma: NCT06910657 Clinical Landscape Report 2026
15 October 2026
NCT06910657 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Benmelstobart in Mismatch repair-deficient Endometrial Carcinoma: NCT06914297 Clinical Landscape Report 2026
15 October 2026
NCT06914297 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
CLBR-001 in Idiopathic Inflammatory Myopathies: NCT06913608 Clinical Landscape Report 2026
15 October 2026
NCT06913608 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Iparomlimab/Tuvonralimab in Advanced Endometrial Carcinoma: NCT06917092 Clinical Landscape Report 2026
15 October 2026
NCT06917092 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Erdafitinib in Non-Muscle Invasive Bladder Neoplasms: NCT06919965 Clinical Landscape Report 2026
15 October 2026
NCT06919965 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
AZD-5492 in Idiopathic Inflammatory Myopathies: NCT06916806 Clinical Landscape Report 2026
15 October 2026
NCT06916806 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Tislelizumab in Carcinoma of urinary bladder, invasive: NCT06916494 Clinical Landscape Report 2026
15 October 2026
NCT06916494 clinical landscape for Carcinoma of urinary bladder, invasive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…